Abbvie Inc Stock Price, News & Analysis

AbbVie (NYSE: ABBV) will disclose its fourth-quarter 2022 financial results on February 9, 2023, prior to market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. CT and can be accessed via AbbVie's Investor Relations website. An archived version will be available later on the same day. AbbVie aims to innovate in various therapeutic areas including immunology, oncology, neuroscience, eye care, virology, and gastroenterology.

AbbVie (NYSE: ABBV) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:00 p.m. CT. The presentation will be led by Richard A. Gonzalez, chairman and CEO. Investors can access a live audio webcast via AbbVie's Investor Relations website, with an archived version available later that day. AbbVie focuses on innovative medicine across critical areas including immunology, oncology, and more. For updates, visit abbvie.com.

AbbVie announced that the FDA has approved VRAYLAR (cariprazine) as an adjunctive treatment for major depressive disorder (MDD) in adults who experience a partial response to standard antidepressant therapy. This approval marks the fourth indication for VRAYLAR, which is the first dopamine and serotonin partial agonist approved for common forms of depression. The clinical trials showed statistically significant improvements in depression symptoms and established tolerability, enhancing treatment options for approximately 20% of U.S. adults who may suffer from MDD.

AbbVie has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. FDA, seeking approval for treating functional constipation in children and adolescents aged 6 to 17. This submission is based on positive results from a Phase 3 trial involving 330 patients, where linaclotide significantly increased spontaneous bowel movement frequency and improved stool consistency compared to placebo. Safety assessments show acceptable tolerability, with diarrhea being the most common adverse event, occurring in 4.3% of linaclotide-treated patients.

AbCellera (Nasdaq: ABCL) has initiated a strategic collaboration with AbbVie (NYSE: ABBV) targeting the development of therapeutic antibodies. This multi-year partnership aims to leverage AbCellera's innovative antibody discovery capabilities for up to five targets across various indications. AbCellera will receive research payments, clinical milestones, and royalties from product sales, indicating potential significant revenue streams. CEO Carl Hansen emphasized the collaboration's focus on solving complex antibody discovery challenges to address critical health issues.

AbbVie presented data on investigational epcoritamab at the 64th ASH Annual Meeting on December 11, 2022. Epcoritamab is being evaluated for relapsed/refractory follicular lymphoma, previously untreated follicular lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and Richter's syndrome. In the EPCORE™ NHL-2 study, 95% of patients with R/R FL achieved an overall response rate, while 94% in the previously untreated FL arm also showed positive results. Epcoritamab's safety profile indicated manageable low-grade cytokine release syndrome (CRS) and common treatment-emergent adverse events.

AbbVie recently presented data from Cohort 3 of the Phase 2 REFINE study at the ASH Annual Meeting, focusing on its investigational drug navitoclax combined with ruxolitinib for JAK inhibitor-naïve myelofibrosis patients. This combination therapy showed promise in reducing bone marrow fibrosis and variant allele frequency associated with myelofibrosis. Notably, spleen volume reduction was observed in various high-risk patient subgroups, and BMF grade improvement was seen in 81% of participants. The study indicates potential disease-modifying effects, although safety assessments showed common adverse events.

AbbVie presented new data at the 64th ASH Annual Meeting on IMBRUVICA (ibrutinib) for chronic lymphocytic leukemia (CLL), focusing on the CAPTIVATE and GLOW studies. Findings showed that patients with confirmed undetectable minimal residual disease experienced high progression-free survival rates, with 95% for those continuing IMBRUVICA vs. 88% for placebo. Additionally, real-world studies indicated that IMBRUVICA treatment yielded longer time to next treatment compared to other therapies. The continued investigation of IMBRUVICA reinforces its position in CLL treatment.